Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Ana Carolina Veneziani

Assistant Professor

University of Toronto

Canada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Canada Professors in Immunology Immunology professors in Canada

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Summary Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing biomarker identified on-target damage to the tumor while minimizing toxicity. A recent article demonstrated high expression of B7-H4 antigen on resistant ovarian cancer cells and described preclinical activity of B7-H4–directed antibody–drug conjugate. See related article by Gitto et al., p. 1567

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (9)

Douglas Millar

University Health Network

CANADA

View details

Amit M Oza

University Health Network

CANADA

View details

C Simon Herrington

Professor

University of Edinburgh

UNITED KINGDOM

View details

Yeh Chen Lee

Staff Medical Oncologist

University of New South Wales

AUSTRALIA

View details

ILARIA COLOMBO

SWITZERLAND

View details

Christoph Grimm

Medical University of Vienna

AUSTRIA

View details

Amit M. Oza

University Health Network

CANADA

View details

Carlos Torrado

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Camila Braganca Xavier

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ana Carolina Veneziani

Research Interests

Make your next move.

Explore related searches

Articles (20)

The evolving role of immunotherapy in ovarian cancer

Antibody-drug conjugates and beyond in platinum-resistant ovarian cancer: A comprehensive review of emergent strategies

Breaking BRCA apart—how important is mutation location and shape in influencing outcome?

Immune checkpoint inhibitors in clear cell ovarian carcinoma and mixed gynecologic clear cell cohorts: a systematic review and meta-analysis

Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial

Multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in patients with advanced gynecological cancers: A prospective study

Multidisciplinary Management of Malignant Bowel Obstruction in Patients with Advanced Gynecological Cancers

Electronic Malignant Bowel Obstruction Symptom Monitoring Smartphone Application for Patients With Gynecologic Cancers

Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile

Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives

EV381/#555 Comprehensive genomic profiling and dynamic monitoring of circulating tumor DNA in patients with small cell carcinoma of the ovary, hypercalcemic type

Molecular characterization of cervical cancer histological subtypes: The VENUS study.

Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in women with advanced gynaecological cancers: A prospective study.

Abstract A074: Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial

Precision oncology for rare gynecologic malignancies: Integrating molecular tumor boards and real-time treatment matching

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Emerging peptide therapeutics for the treatment of ovarian cancer

Heterogeneity and treatment landscape of ovarian carcinoma

806P Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers

Collaborators (9)

Douglas Millar

Amit M Oza

C Simon Herrington

Yeh Chen Lee

ILARIA COLOMBO

Christoph Grimm

Amit M. Oza

Carlos Torrado

Camila Braganca Xavier

Make your next move.